Literature DB >> 125040

Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease.

G W DeVane, N M Czekala, H L Judd, S S Yen.   

Abstract

Serum gonadotropin, estrogen, and androgen levels were measured in samples obtained from 19 patients with polycystic ovarian disease (PCO) and from 10 normal women on day 2 to 4 of their menstrual cycles. In patients with PCO, the mean (plus or minus S.E.) concentration was significantly higher (P smaller than 0.001) than the concentrations found in the normal subjects for LH (35 plus or minus 4.6 vs. 12.7 plus or minus 2.6 m.I.U. per milliliter), but not for FSH (10.3 plus or minus 0.7 vs. 8.7 plus or minus 0.9 m.I.U. per milliliter). Estrone (E1) levels (92 plus or minus 4 vs. 52 plus or minus 5 pg. per milliliter) were also significantly higher (P smaller than 0.001), while estradiol (E2) concentrations (58 plus or minus 4 vs. 63 plus or minus 8 pg. per milliliter) were comparable. Testosterone (T) (468 plus or minus 41 vs. 325 plus or minus 34 pg. per milliliter, P smaller than 0.05), androstenedione (delta) (2,083 plus or minus 138 vs. 1,123 plus or minus 153 pg. per milliliter, P smaller than 0.001), and dehydroepiandrosterone sulfate (3.4 plus or minus 0.4 vs. 2.0 plus or minus 0.37 mug per milliliter, P smaller 0.02) were also significantly increased over the values in normal controls. The mean dehydroepiandrosterone (DHEA) was elevated in the patients with PCO (11.3 plus or minus 1.7 vs. 7.5 plus or minus 1.2 mug per milliliter), but was not significantly different. A positive correlation was found between LH levels and both E2 and E1 concentrations in the patients with PCO. These data show a distinct profile of gonadotropin, estrogen, and androgen levels in patients with PCO.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 125040     DOI: 10.1016/0002-9378(75)90081-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  28 in total

1.  Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.

Authors:  T J Gelety; E S Surrey
Journal:  J Assist Reprod Genet       Date:  1997-10       Impact factor: 3.412

2.  Dietary protein intake and bone mass in women.

Authors:  C Cooper; E J Atkinson; D D Hensrud; H W Wahner; W M O'Fallon; B L Riggs; L J Melton
Journal:  Calcif Tissue Int       Date:  1996-05       Impact factor: 4.333

3.  The polycystic ovary syndrome:psychosexual correlates.

Authors:  G Gorzynski; J L Katz
Journal:  Arch Sex Behav       Date:  1977-05

Review 4.  Emerging roles for noncoding RNAs in female sex steroids and reproductive disease.

Authors:  Runju Zhang; Victoria Wesevich; Zhaojuan Chen; Dan Zhang; Amanda N Kallen
Journal:  Mol Cell Endocrinol       Date:  2020-07-12       Impact factor: 4.102

Review 5.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

6.  Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase.

Authors:  L Nathan; W Shi; H Dinh; T K Mukherjee; X Wang; A J Lusis; G Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

7.  Polycystic ovary syndrome and (pre)osteoarthritis: assessing the link between hyperandrogenism in young women and cartilage oligomeric matrix protein as a marker of cartilage breakdown.

Authors:  Plamena Kabakchieva; Tsvetoslav Georgiev; Antoaneta Gateva; Julieta Hristova; Zdravko Kamenov
Journal:  Clin Rheumatol       Date:  2021-05-04       Impact factor: 2.980

8.  Polycystic ovary syndrome: an enigma awaiting solution.

Authors:  M Schwartz; P R Gindoff; R Jewelewicz
Journal:  Bull N Y Acad Med       Date:  1987-03

9.  Pituitary and adrenal response to ovine corticotropin-releasing hormone in women with polycystic ovarian syndrome.

Authors:  A Mongioì; M Macchi; E Vicari; M C Fornito; A E Calogero; C Riccioli; G Minacapilli; M L Moncada; R D'Agata
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

Review 10.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.